Swiss regulator approves Roche-Regeneron Covid-19 drug
Monoclonal treatment
Sun Sentinel 2021
The Swiss medicines agency, Swissmedic, has given the green light to the monoclonal antibody cocktail Ronapreve developed by Roche and Regeneron for use in the treatment and prevention of Covid-19.
Ronapreve, a combination of two monoclonal antibodies (casirivimab and imdevimab), is approved for patients 12 years and up when “oxygen therapy or hospitalisation is not required and there is a high risk of developing a severe form of Covid-19,” Swissmedic said in a statementExternal link.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses.
The treatment can also be taken prophylactically when the immune response to Covid-19 vaccination is not adequate. It is the first drug authorised by the Swiss regulator for the prevention of Covid-19 in cases where there is not a sufficient immune response after vaccination due to other diseases or treatments.
Ronapreve is given as a single infusion into a vein or by injection under the skin. The application for the authorisation of the drug, submitted on March 5, didn’t include data on the efficacy of the drug against the Omicron variant.
Since-April, Ronapreve could be administered under the exceptions allowed in the Covid-19 Ordinance 3; an ordinance published by the Federal Council in June 2020 to combat the pandemic. This includes a list of products that can be placed on the market before the authorisation procedure is concluded.
The antibody cocktail has been authorised in several other locations including in Japan and the European Union. It has a conditional approval in the UK and Australia and is available for emergency use in the United States.
More orders
The Federal Office of Public Health (FOPH) has been building up its Covid-19 treatment reserves. On Monday, the FOPH announced that it had signed two additional contracts for more doses of both Ronapreve (4,000 doses) and the monoclonal drug sotrovimab (2,000 doses) developed by GlaxoSmithKline and Vir Biotechnology. The antibody for the latter was discovered by Swiss company Humabs BioMed.
This is on top of the 3,000 doses of each drug the government ordered earlier this year. Contract amounts are confidential for both drugs, according to the FOPH.
Popular Stories
More
Swiss Abroad
Heimatort, sweet Heimatort: the unique Swiss concept of home
PostFinance cancels accounts of customers with Cuba links
This content was published on
The financial services arm of the Swiss post office, PostFinance, has cancelled the accounts of several customers with links to Cuba as a consequence of US sanctions against the Caribbean island state.
Basel cannabis study reports improvements in smokers’ mental health
This content was published on
After two years, a legal recreational cannabis study known as "Weedcare", carried out in Basel in northwestern Switzerland, has been given a positive assessment.
Group reports rise in anti-Semitic incidents in French-speaking Switzerland
This content was published on
Anti-Semitic incidents rose by almost 90% in French-speaking Switzerland last year, according to the Intercommunity Coordination Against Anti-Semitism and Defamation (known by its French name CICAD).
Number of Swiss around the world grew by 1.6% in 2024
This content was published on
Last year, 13,300 Swiss citizens moved abroad, taking the total number of Swiss Abroad to 826,700 (+1.6%). Three-quarters have more than one nationality, new figures show.
ICRC pleads for release of German nurse held in Somalia for seven years
This content was published on
The Geneva-based International Committee of the Red Cross (ICRC) has called for the release of Sonja Nientiet, one of its nurses who was kidnapped in Somalia in 2018.
This content was published on
A Swiss court says the cantonal authorities in Geneva should not have introduced a 30 km/h speed limit on its local roads.
Swiss ambassador calls for more exercises with NATO
This content was published on
The Swiss ambassador to Belgium and NATO, Jacques Pitteloud, has called for Switzerland to participate in more NATO exercises.
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
This content was published on
Swiss biopharma firm Roche has been granted emergency authorisation by US authorities to sell its at-home rapid Covid-19 test starting in January.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.